# DurAVR™ THV System: EMBARK Study

Study · id `cardio:ct-nct05182307` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05182307](<https://clinicaltrials.gov/study/NCT05182307>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05182307

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05182307. Allocation not applicable; no masking; primary purpose device feasibility. Start 2021-11-15 (actual); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose device feasibility
- Phase: Not applicable
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05182307, source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)
- Started: 2021-11-15 (actual) (ClinicalTrials.gov record NCT05182307, source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT05182307, source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT05182307, source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)
- Countries: Georgia (ClinicalTrials.gov record NCT05182307, source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05182307-2026-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: DurAVR™ THV System: EMBARK Study
- Condition: Symptomatic Aortic Stenosis
- Condition: Severe Aortic Valve Stenosis
- Condition: Aortic Valve Calcification
- Intervention (Device): DurAVR™ THV System
- Lead sponsor: Anteris Technologies Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 2bd01320c656c6c4b7846aa4d1bb4d7477680225ba65c4f02fc6dbce5abedd79
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
